Abstract
Hodgkin lymphoma (HL) is a curable malignancy for most patients, while the treatment of relapsed and refractory (R/R) HL is still facing severe challenges. In the 60th American Society of Hematology(ASH) Annual Meeting, many researches reported the latest development of the treatment of R/R HL. For chemosensitive patients, autologous stem cell transplantation after high-dose of salvage chemotherapy still remains the standard treatment method. The emerging of antibody drug conjugate, inhibitors of programmed death-1, chimeric antigen receptor T-cell immunotherapy and the combinations of multiple drugs have brought an increasing options for R/R HL treatment. This paper reviews the progress of R/R HL therapy. Key words: Hodgkin disease; Recurrence; Refractory
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
